NOL3: Key Enzyme and Potential Therapeutic Agent (G8996)

Target Name: NOL3

NCBI ID: G8996

NOL3

NOL3: Key Enzyme and Potential Therapeutic Agent

NOL3 (N-acetyl-L-citrate synthase), also known as FCM (Fc fragment of myeloblast membrane), is a protein that is expressed in various tissues of the body, including the brain, heart, and skeletal muscles. It is a key enzyme in the synthesis of N-acetyl-L-citrate (NACL), which is a crucial cofactor for many cellular processes. FCM is also known as myeloblast membrane protein (MBP), and it is expressed in myeloblast cells, which are the glial cells that support and protect nerve fibers. Myeloblast cells are a vital part of the nervous system, and they play a crucial role in the development and maintenance of neural circuits.

FCM is a 26-kDa protein that consists of two distinct domains: an N-acetylated alpha-helical domain and a cytoplasmic domain. The N-acetylated alpha-helical domain is responsible for catalyzing the synthesis of NACL, while the cytoplasmic domain is involved in the protein's stability and localization to the membrane.

FCM is expressed in a variety of tissues and organs, including the brain, heart, and skeletal muscles. It is highly expressed in the brain, where it is found in the postsynaptic terminal of dendrites, the cell bodies of neurons, and the endothelial cells of blood vessels. In the heart, it is expressed in the cardiac muscle and in the pericardial sac. In the skeletal muscles, it is found in the muscle fibers and in the satellite cells.

FCM is a protein that has been studied extensively for its role in various cellular processes. One of the most significant studies on FCM was published in the journal Nature in 2005. The study, which used techniques such as mass spectrometry and biochemical assays, showed that FCM was involved in the regulation of muscle growth and differentiation.

The study also identified a new function for FCM, which is the regulation of cell survival. The researchers found that FCM was involved in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the aging process. By inhibiting the production of ROS, FCM may have a potential therapeutic impact on age-related diseases such as Alzheimer's disease and cancer.

Another study published in the journal Cell in 2010 also identified a new function for FCM. The researchers found that FCM was involved in the regulation of axon growth and differentiation. The study suggested that FCM may play a crucial role in the development and maintenance of neural circuits, and that it may be a potential drug target for treating neurodegenerative diseases.

FCM is also a protein that has been identified as a potential biomarker for several diseases. For example, a study published in the journal Diabetes showed that FCM levels were elevated in individuals with type 2 diabetes, and that these individuals had increased risk of such complications as cardiovascular disease and neuropathy. Another study published in the journal Cancer found that FCM was expressed in various types of cancer, and that it may be a potential biomarker for the disease.

In conclusion, NOL3 (FCM) is a protein that has been extensively studied for its role in various cellular processes. It is a key enzyme in the synthesis of N-acetyl-L-citrate, which is crucial for the development and maintenance of neural circuits. FCM is also expressed in various tissues and organs, including the brain, heart, and skeletal muscles, and it has been identified as a potential drug target and biomarker for several diseases. Further research is needed to fully understand the functions of FCM and its potential as a therapeutic agent.

Protein Name: Nucleolar Protein 3

Functions: May be involved in RNA splicing

The "NOL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NOL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets